Gilead Sciences: Does Hepatitis-B Failure Mean More M&A?
May 27, 2015 at 11:57 AM EDT
Gilead Sciences (GILD) reported that the hepatitis-B treatment its developing with GlobeImmune (GBIM) failed in a drug trial. RBC’s Michael Yee and team look for the silver lining in the cloud: Bloomberg GS-4774 in partnership with GlobeImmune for Hep B missed the Phase II primary endpoint of S-antigen reduction at 24 weeks. The good news with [...]
